Vicky L Ng1, Ruosha Li, Kathleen M Loomes, Mike A Leonis, David A Rudnick, Steven H Belle, Robert H Squires. 1. *Division of Paediatric Gastroenterology, Hepatology and Nutrition, Transplant and Regenerative Medicine Center, The Hospital for Sick Children, University of Toronto, Toronto, Canada †Department of Biostatistics, University of Texas School of Public Health, Houston ‡Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia §Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia ||Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center ¶Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH #Department of Pediatrics and Developmental Biology, Washington University School of Medicine, St. Louis, MO **Department of Epidemiology and Biostatistics, Graduate School of Public Health, University of Pittsburgh ††Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA.
Abstract
OBJECTIVES: Hepatic encephalopathy (HE) is challenging to identify in children with acute liver failure and was not a requirement for enrollment into the Pediatric Acute Liver Failure Study Group (PALFSG). The outcomes of PALFSG participants presenting with and without HE are presented. METHODS: PALFSG participants were classified based on daily assessment of HE during the first 7 days following study enrollment: group 1-never developed HE; group 2-no HE at enrollment with subsequent HE development; and group 3-HE at study enrollment. Clinical and biochemical parameters and outcomes of death, spontaneous recovery, or liver transplantation were compared between groups. RESULTS: Data from 769 PALFSG (54% boys; median age 4.2 years; range 0-17.9 years) participants were analyzed, with 277 in group 1 (36%), 83 in group 2 (11%), and 409 in group 3 (53%). Mortality occurred in 11% of all participants and was highest among group 3 participants who demonstrated persistent grade III-IV HE (55%) or showed progression of HE (26%). Eleven (4%) group 1 participants died within 21 days of enrollment. Spontaneous recovery was highest in group 1 (79%) and lowest in group 2 (25%; P < 0.001). CONCLUSIONS: Mortality 21 days after enrollment was highest in participants enrolled with severe HE (grades III or IV) or demonstrating HE progression. Four percent of participants without recorded clinical HE in the 7 days after enrollment, however, died within 21 days. Improved assessment of neurological injury and pediatric acute liver failure prognostication schema are needed.
OBJECTIVES:Hepatic encephalopathy (HE) is challenging to identify in children with acute liver failure and was not a requirement for enrollment into the Pediatric Acute Liver Failure Study Group (PALFSG). The outcomes of PALFSG participants presenting with and without HE are presented. METHODS: PALFSG participants were classified based on daily assessment of HE during the first 7 days following study enrollment: group 1-never developed HE; group 2-no HE at enrollment with subsequent HE development; and group 3-HE at study enrollment. Clinical and biochemical parameters and outcomes of death, spontaneous recovery, or liver transplantation were compared between groups. RESULTS: Data from 769 PALFSG (54% boys; median age 4.2 years; range 0-17.9 years) participants were analyzed, with 277 in group 1 (36%), 83 in group 2 (11%), and 409 in group 3 (53%). Mortality occurred in 11% of all participants and was highest among group 3 participants who demonstrated persistent grade III-IV HE (55%) or showed progression of HE (26%). Eleven (4%) group 1 participants died within 21 days of enrollment. Spontaneous recovery was highest in group 1 (79%) and lowest in group 2 (25%; P < 0.001). CONCLUSIONS: Mortality 21 days after enrollment was highest in participants enrolled with severe HE (grades III or IV) or demonstrating HE progression. Four percent of participants without recorded clinical HE in the 7 days after enrollment, however, died within 21 days. Improved assessment of neurological injury and pediatric acute liver failure prognostication schema are needed.
Authors: Robert H Squires; Benjamin L Shneider; John Bucuvalas; Estella Alonso; Ronald J Sokol; Michael R Narkewicz; Anil Dhawan; Philip Rosenthal; Norberto Rodriguez-Baez; Karen F Murray; Simon Horslen; Martin G Martin; M James Lopez; Humberto Soriano; Brendan M McGuire; Maureen M Jonas; Nada Yazigi; Ross W Shepherd; Kathleen Schwarz; Steven Lobritto; Daniel W Thomas; Joel E Lavine; Saul Karpen; Vicky Ng; Deirdre Kelly; Nancy Simonds; Linda S Hynan Journal: J Pediatr Date: 2006-05 Impact factor: 4.406
Authors: William A Bower; Matthew Johns; Harold S Margolis; Ian T Williams; Beth P Bell Journal: Am J Gastroenterol Date: 2007-06-29 Impact factor: 10.864
Authors: Michael R Narkewicz; Simon Horslen; Regina M Hardison; Benjamin L Shneider; Norberto Rodriguez-Baez; Estella M Alonso; Vicky L Ng; Mike A Leonis; Kathleen M Loomes; David A Rudnick; Philip Rosenthal; Rene Romero; Girish C Subbarao; Ruosha Li; Steven H Belle; Robert H Squires Journal: Clin Gastroenterol Hepatol Date: 2018-04-30 Impact factor: 11.382
Authors: Nicole A Toney; Michael J Bell; Steven H Belle; Regina M Hardison; Norberto Rodriguez-Baez; Kathleen M Loomes; Yoram Vodovotz; Ruben Zamora; Robert H Squires Journal: J Pediatr Gastroenterol Nutr Date: 2019-07 Impact factor: 2.839
Authors: James E Squires; David A Rudnick; Regina M Hardison; Simon Horslen; Vicky L Ng; Estella M Alonso; Steven H Belle; Robert H Squires Journal: Hepatology Date: 2018-11-01 Impact factor: 17.425